National Bank of Canada
EPRX

National Bank of Canada’s Eupraxia Pharmaceuticals EPRX Stock Holding History

National Bank of Canada’s Portfolio EPRX Stock Details EPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$812 Sell
359
-227
-39% -$1.83K ﹤0.01% 2697
2025
Q4 		$4.44K Sell
586
-296
-34% -$1.82K ﹤0.01% 2454
2025
Q3 		$5.03K Buy
882
+152
+21% +$827 ﹤0.01% 2457
2025
Q2 		$3.91K Sell
730
-34
-4% -$131 ﹤0.01% 2535
2025
Q1 		$2.49K Buy
764
+721
+1,677% +$2.49K ﹤0.01% 2476
2024
Q4 		$135 Sell
43
-107
-71% -$317 ﹤0.01% 2779
2024
Q3 		$394 Buy
+150
New +$394 ﹤0.01% 2495

Other funds holding EPRX

BGC
Beutel, Goodman & Co Toronto, Ontario, Canada $14.8B AUM 15.12% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
SC
Scotia Capital Toronto, Ontario, Canada $24.3B AUM 29.21% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

National Bank of Canada's EPRX Position: Q1 2026 in Review

National Bank of Canada reduced its Eupraxia Pharmaceuticals (EPRX) stake by 39% in Q1 2026, selling an estimated $1.83K and leaving 359 shares worth $812. The position accounts for ﹤0.01% of the portfolio, ranked #2697.

National Bank of Canada first reported a position in EPRX in Q3 2024 and has held it in 7 quarters since. The position peaked at $5.03K in Q3 2025. 54 funds tracked by Wall St. Rank hold EPRX as of Q1 2026.

  • National Bank of Canada held 359 shares of Eupraxia Pharmaceuticals worth $812 as of Q1 2026.
  • National Bank of Canada sold 227 Eupraxia Pharmaceuticals shares in Q1 2026, an estimated $1.83K.
  • Eupraxia Pharmaceuticals made up ﹤0.01% of National Bank of Canada's portfolio in Q1 2026, its #2697 holding.
  • National Bank of Canada first reported a position in Eupraxia Pharmaceuticals in Q3 2024 and has held it in 7 quarters since.
  • National Bank of Canada's Eupraxia Pharmaceuticals position peaked at $5.03K in Q3 2025.
  • 54 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q1 2026.

Based on National Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.